Search results
Fundamental Research Paved the Way for the Development of Vorasidenib
National Cancer Institute· 5 days agoDuring the 2023 American Society of Clinical Oncology (ASCO) annual meeting, a plenary presentation...
Mass. community organizes parade for 8-year-old cancer patient
WCVB Boston· 2 days agoAdelia, who is known as "Adelia the Wonder Girl" on social media, was diagnosed with diffuse midline...
Researchers discover benefits of adding immune-boosting agent to personalized cancer vaccine
Medical Xpress· 7 days agoThe study, published in Nature Communications, found that pairing a personalized dendritic cell...
New Sylvester Brain Tumor Institute offering personalized treatment
CBS News· 14 hours agoThere's a new way to treat patients with brain cancer at UM's Sylvester Comprehensive Cancer Center.
Candel Lights Up Investors' Portfolio With 830% Gain
RTT News· 10 hours agoShares of Candel Therapeutics Inc. (CADL) have gained more than 830% in the past 2 months, thanks to the substantial progress achieved across its clinical programs.
Phosphoglycerate mutase 1 promotes breast cancer progression through inducing immunosuppressive M2...
Nature· 1 day agoImmunosuppressive tumor microenvironment (TME) contributes to tumor progression and causes major obstacles for cancer therapy. Phosphoglycerate mutase 1 (PGAM1) is a key enzyme involved in cancer ...
Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise
MedPage Today· 6 days agoNews, features, and commentary about cancer-related issues
Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results
Proactive Investors· 6 days agoMazzo highlighted Lisata's effective cash management, with over $43 million in funds ensuring...
Earnings call: Cyclacel Pharmaceuticals reports Q1 2024 results
Investing.com· 1 day agoCyclacel Pharmaceuticals , Inc. (NASDAQ: CYCC ) has provided its first quarter financial results and...
Chimerix (NASDAQ:CMRX) Upgraded by StockNews.com to “Hold”
ETF DAILY NEWS· 2 days agoStockNews.com upgraded shares of Chimerix (NASDAQ:CMRX – Free Report) from a sell rating to a hold rating in a report issued on Monday morning. CMRX has been the subject of several other research ...